DK1634498T3 - Exo-S-mecamylamine formulation - Google Patents

Exo-S-mecamylamine formulation

Info

Publication number
DK1634498T3
DK1634498T3 DK05024899T DK05024899T DK1634498T3 DK 1634498 T3 DK1634498 T3 DK 1634498T3 DK 05024899 T DK05024899 T DK 05024899T DK 05024899 T DK05024899 T DK 05024899T DK 1634498 T3 DK1634498 T3 DK 1634498T3
Authority
DK
Denmark
Prior art keywords
exo
mecamylamine
pharmaceutically acceptable
disorder
amount
Prior art date
Application number
DK05024899T
Other languages
English (en)
Inventor
Douglas Shytle
Paul Sanberg
Mary Newman
Archie Silver
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of DK1634498T3 publication Critical patent/DK1634498T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK05024899T 1998-12-16 1999-12-16 Exo-S-mecamylamine formulation DK1634498T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11253498P 1998-12-16 1998-12-16
PCT/US1999/030137 WO2000035280A1 (en) 1998-12-16 1999-12-16 Exo-r-mecamylamine formulation and use in treatment

Publications (1)

Publication Number Publication Date
DK1634498T3 true DK1634498T3 (da) 2008-12-15

Family

ID=22344414

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99967401T DK1139743T3 (da) 1998-12-16 1999-12-16 Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger
DK05024899T DK1634498T3 (da) 1998-12-16 1999-12-16 Exo-S-mecamylamine formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK99967401T DK1139743T3 (da) 1998-12-16 1999-12-16 Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger

Country Status (12)

Country Link
US (1) US20020016370A1 (da)
EP (3) EP1139743B1 (da)
JP (5) JP2002532393A (da)
AT (2) ATE320711T1 (da)
AU (2) AU2368600A (da)
CA (2) CA2393437C (da)
CY (1) CY1108577T1 (da)
DE (2) DE69930552T2 (da)
DK (2) DK1139743T3 (da)
ES (2) ES2260959T3 (da)
PT (2) PT1634498E (da)
WO (2) WO2000035280A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
KR20050096922A (ko) 2002-12-20 2005-10-06 니코노범 에이비 물리적 및 화학적으로 안정된 니코틴 함유 입자물질
US20070224284A1 (en) * 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
JP2010505960A (ja) * 2006-10-09 2010-02-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ニコチン禁断症状および／またはタバコ使用の軽減用組成物
US20090018407A1 (en) * 2007-03-30 2009-01-15 Searete Llc, A Limited Corporation Of The State Of Delaware Computational user-health testing
US20080243005A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090119154A1 (en) * 2007-11-07 2009-05-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content
US20080242952A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Effective response protocols for health monitoring or the like
US20080319276A1 (en) * 2007-03-30 2008-12-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242951A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20090005653A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242949A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090005654A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242948A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20080242947A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Configuring software for effective health monitoring or the like
GB2448224B (en) * 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
JP2012533547A (ja) * 2009-07-14 2012-12-27 ターガセプト，インコーポレイテッド 治療のためのエキソ−ｓ−メカミラミンの方法、使用、及び化合物
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
PL2576496T3 (pl) 2010-05-27 2017-08-31 Catalyst Biosciences, Inc. Niekompetycyjni antagoniści receptorów nikotynowych
AT510837B1 (de) 2011-07-27 2012-07-15 Helmut Dr Buchberger Inhalatorkomponente
EP2672847B1 (de) 2011-02-11 2015-04-22 Batmark Limited Inhalatorkomponente
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
KR101870335B1 (ko) 2011-09-06 2018-07-20 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 가열식 끽연 가능 물질
PL2753202T3 (pl) 2011-09-06 2016-11-30 Podgrzewanie materiału przeznaczonego do palenia
AT511344B1 (de) 2011-10-21 2012-11-15 Helmut Dr Buchberger Inhalatorkomponente
US8901177B2 (en) * 2012-03-23 2014-12-02 Targacept, Inc. Method of treating bladder disorders
GB201207039D0 (en) 2012-04-23 2012-06-06 British American Tobacco Co Heating smokeable material
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB2513639A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2513637A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2514893B (en) 2013-06-04 2017-12-06 Nicoventures Holdings Ltd Container
GB201407426D0 (en) 2014-04-28 2014-06-11 Batmark Ltd Aerosol forming component
GB2528673B (en) 2014-07-25 2020-07-01 Nicoventures Holdings Ltd Aerosol provision system
US10080726B2 (en) 2014-08-22 2018-09-25 Atacama Therapeutics, Inc. Method for treating hyperhidrosis with dexmecamylamine
GB2533135B (en) 2014-12-11 2020-11-11 Nicoventures Holdings Ltd Aerosol provision systems
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
GB201511349D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US20170119046A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Apparatus for Heating Smokable Material
CA3022340C (en) 2016-04-27 2021-09-21 Nicoventures Holdings Limited Electronic aerosol provision system and vaporizer therefor
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
GB202203728D0 (en) * 2022-03-17 2022-05-04 Univ Oxford Innovation Ltd Treatments and methods for increasing dopamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039801A (en) * 1985-12-20 1991-08-13 The United States Of America As Represented By The Department Of Health & Human Services Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
EP0579260A1 (en) * 1987-07-07 1994-01-19 Beecham Group Plc Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Also Published As

Publication number Publication date
DE69939498D1 (de) 2008-10-16
PT1139743E (pt) 2006-06-30
ATE320711T1 (de) 2006-04-15
JP2014051528A (ja) 2014-03-20
EP1139744A1 (en) 2001-10-10
DE69930552D1 (de) 2006-05-11
ATE406797T1 (de) 2008-09-15
CY1108577T1 (el) 2014-04-09
WO2000035279A1 (en) 2000-06-22
EP1634498B1 (en) 2008-09-03
CA2393442A1 (en) 2000-06-22
ES2313187T3 (es) 2009-03-01
WO2000035280A1 (en) 2000-06-22
EP1139743A4 (en) 2003-01-02
EP1139743B1 (en) 2006-03-22
AU2368600A (en) 2000-07-03
JP2002532393A (ja) 2002-10-02
DK1139743T3 (da) 2006-07-31
ES2260959T3 (es) 2006-11-01
CA2393437A1 (en) 2000-06-22
EP1634498A3 (en) 2006-03-29
US20020016370A1 (en) 2002-02-07
CA2393437C (en) 2009-12-15
JP2002532392A (ja) 2002-10-02
JP2011126909A (ja) 2011-06-30
JP2016065108A (ja) 2016-04-28
DE69930552T2 (de) 2006-11-30
EP1139743A1 (en) 2001-10-10
AU2368200A (en) 2000-07-03
EP1139744A4 (en) 2003-01-02
EP1634498A2 (en) 2006-03-15
PT1634498E (pt) 2008-10-28

Similar Documents

Publication Publication Date Title
ATE406797T1 (de) Exo-s-mecamylamin-formulierung
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
BR0206559A (pt) Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto
ATE253039T1 (de) Beta 2 -adrenergische rezeptor-agonisten
WO2002043652A3 (en) Anti-proliferative drugs
JP2002532392A5 (da)
Summers et al. THA—a review of the literature and its use in treatment of five overdose patients
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
ATE433959T1 (de) Analoge von kokain
DK1212060T3 (da) Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom
Sun et al. Management of tetanus: a review of 18 cases
NO317485B1 (no) Fremgangsmate for fremstilling av ZME-018 gelonin immunokonjugat for behandling av melanom
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
Durant et al. Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat and rhesus monkey
Feinberg et al. Methadone and schizophrenia.
GR3001420T3 (en) Prazosin-pirbuterol combination for bronchodilation
Mison-Crighel et al. Glutaminase activity and neocortical excitability
NZ224502A (en) Silyl alkylene amines and pharmaceutical use, methods for preparation and the treatment of non humans
Booij The history of neuromuscular blocking agents
CA2511664A1 (en) 4',4''-substituted 3.alpha.-(diphenylmethoxy)tropane analogs for treatment of mental disorders
KR100403722B1 (en) Lower alcohol insoluble extract of hovenia dulcis thunberg having liver protection activity, polysaccharide separated therefrom and composition containing the same
Messer et al. Synthesis, biochemical activity and behavioral effects of a series of 1, 4, 5, 6-tetrahydropyrimidines as novel ligands for M1 receptors
KR920000717A (ko) 디클로로아닐린 화합물
EP1404341A1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
RU2192275C2 (ru) Способ лечения опийной наркомании